Flatiron announced a three-year agreement with Bristol-Myers Squibb (BMS) a leading pharma company from the US. BMS is planning to use Flatiron’s expertise to expand real-world evidence to develop Bristol’s experimental cancer drugs.
The American Heart Association, one of the leading non-profit organizations that foster cardiac care, is working to enhance community health through a new business line - Health Screening Services (HSS). The new health screening services will help consumers become more conscious of personal health risk factors and motivate them to make changes in their behaviors and lifestyle.
In the first quarter of 2018, Swiss pharmaceuticals and diagnostics player Roche group’s sales rose by 6% to CHF 13.6 billion. Sales in the pharma division increased by 7% CHF 10.7 billion mainly by strong growth in Ocrevus and Perjeta.
The University Of Kansas Medical Center is partnering with Garmin Health to foster innovation and better understand on how healthcare wearables can help in the detection and management of significant medical conditions. Their first research will focus on cardiac care and sleep apnea.
California-based Casetabs, the pioneer of cloud-based surgery coordination technology, yesterday announced it has received $6 million in series A-funding to scale its surgery coordination application.
US patient-centric data analytics company, Trayt Technologies (formerly Ava Health), has developed an app to help improve the diagnosis, treatment, and quality of life for patients with autism, ADHD and other neurodevelopmental and brain disorders.
Based on data from the phase II JULIET study, tisagenlecleucel (Kymriah) has received FDA approval for the treatment of adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.